Highlights
- 1,284 bladder cancer patients spanning non-muscle-invasive (NMIBC) and muscle-invasive bladder cancer (MIBC), with extensive clinical annotation and longitudinal follow-up
- more than five years of linked outcomes data including recurrence, progression, treatment exposure and survival
- large-scale molecular profiling, including targeted tumour sequencing for 956 patients and germline genotyping for 780 patients
- ~1,000 digitised pathology samples (tissue microarray) with biomarker Immunohistochemistry (IHC) data
- 252 non-bladder cancer controls available for comparative and classification studies
The opportunity
The Bladder Cancer Prognosis Programme (BCPP) is a large, clinically linked bladder cancer resource comprising 1,284 newly diagnosed patients across both NMIBC and MIBC. It includes an additional 252 non-bladder cancer controls for comparative analyses.
A key strength of BCPP is its extensive clinical database. This combines baseline patient and tumour characteristics with treatment history, recurrence, progression, and survival outcomes collected through longitudinal follow-up (minimum of five years).
The resource includes a diverse range of molecular and imaging datasets generated from tumour, blood and urine samples. The datasets include:
- targeted tumour sequencing in more than 950 patients
- germline genotyping
- transcriptomic profiling
- proteomic data
- digitised pathology images with IHC for multiple clinically relevant biomarkers
BCPP is a valuable resource for translational research, enabling studies of the molecular drivers of recurrence and progression, development of prognostic and predictive biomarkers, and multimodal analyses combining pathology, genomics and clinical outcomes. The scale of the clinical cohort, together with the breadth of available molecular and imaging data, makes BCPP a powerful resource for precision medicine research and innovation in bladder cancer.
Contact
